Shattuck Labs (NASDAQ:STTK) Issues Earnings Results

Shattuck Labs (NASDAQ:STTK) announced its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01, FiscalAI reports. The firm had revenue of $1.00 million during the quarter.

Shattuck Labs Stock Performance

Shattuck Labs stock traded down $0.08 during trading on Thursday, reaching $1.96. The company had a trading volume of 108,901 shares, compared to its average volume of 249,310. Shattuck Labs has a 12-month low of $0.69 and a 12-month high of $2.70. The stock’s 50 day moving average price is $1.97 and its two-hundred day moving average price is $1.29. The firm has a market capitalization of $93.88 million, a price-to-earnings ratio of -1.62 and a beta of 1.88.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on STTK shares. Leerink Partners dropped their target price on shares of Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Thursday, August 14th. Wall Street Zen raised shares of Shattuck Labs from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a research note on Wednesday, October 8th. Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, August 14th. Finally, Wedbush assumed coverage on shares of Shattuck Labs in a report on Monday, September 8th. They set an “outperform” rating and a $4.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $3.00.

Insider Buying and Selling

In related news, Director Mona Ashiya bought 6,306,127 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was purchased at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the completion of the acquisition, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. This trade represents a -600.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Orbimed Advisors Llc bought 6,306,127 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the acquisition, the director owned 5,255,106 shares of the company’s stock, valued at $4,571,942.22. This trade represents a -600.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 12.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Shattuck Labs

Several institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC grew its stake in Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after buying an additional 31,355 shares during the period. Bridgeway Capital Management LLC grew its stake in Shattuck Labs by 147.5% during the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after buying an additional 55,000 shares during the period. Qube Research & Technologies Ltd purchased a new stake in Shattuck Labs during the second quarter worth approximately $44,000. Acadian Asset Management LLC grew its stake in Shattuck Labs by 27.6% during the first quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock worth $243,000 after buying an additional 55,687 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Shattuck Labs during the first quarter worth approximately $81,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.